Physician profile
Mary E Garman
NPI 1346277381
$22,532.67
in general payments reported to CMS, 2019-2025
37 companies · $3,885 in 2025
The $3,885 reported for 2025 was more than what 88% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,730 · 2020: $1,507 · 2021: $2,486 · 2022: $3,524 · 2023: $4,256 · 2024: $4,145 · 2025: $3,885.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,118.91 |
| Education | $166.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,069.04 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $2,192.59 | 2019-2025 | |
| Janssen Biotech, INC. | $2,155.78 | 2019-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $1,654.10 | 2019-2025 | Dupixent |
| Amgen INC. | $1,339.07 | 2019-2025 | Otezla, Otezla |
| Incyte Corporation | $1,196.33 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $1,187.54 | 2019-2025 | Adbry, Spevigo |
| Lilly USA, LLC | $1,113.52 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Genzyme Corporation | $977.04 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $916.82 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $698.88 | 2019-2025 | Aklief, Nemluvio, Oracea |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $682.53 | 2019-2025 | Siliq, Targretin, Jublia |
| Sun Pharmaceutical Industries INC. | $634.42 | 2019-2025 | Ilumya |
| Pfizer INC. | $589.84 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $549.21 | 2022-2025 | Sotyktu |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $404.07 | 2019 | |
| Dermavant Sciences, INC. | $402.88 | 2022-2024 | Vtama |
| Mayne Pharma Commercial LLC | $327.51 | 2019-2025 | |
| Hill Dermaceuticals, INC. | $236.91 | 2021-2025 | Tolak |
| Almirall LLC | $211.47 | 2020-2025 | Klisyri, Seysara |
| Epi Health, LLC | $174.75 | 2019-2022 | |
| Dermira, INC. | $124.67 | 2019-2021 | |
| Ucb, INC. | $119.41 | 2019-2025 | Bimzelx |
| Medimetriks Pharmaceuticals, INC. | $77.14 | 2020-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.16 | 2022-2023 | Spevigo |
| Encore Dermatology INC. | $68.00 | 2019-2020 | |
| Biofrontera INC. | $66.42 | 2019-2021 | |
| Paratek Pharmaceuticals, INC. | $46.95 | 2021 | |
| Genentech USA, INC. | $44.25 | 2020-2024 | Erivedge |
| Verrica Pharmaceuticals INC. | $35.61 | 2024-2025 | Ycanth |
| Vyne Pharmaceuticals INC. | $28.57 | 2020 | |
| Journey Medical Corporation | $26.95 | 2020 | |
| Tempus Ai, INC | $26.59 | 2024 | Merlin Test |
| Organon LLC | $25.25 | 2025 | Vtama |
| Allergan, INC. | $22.71 | 2019 | |
| Sandoz INC. | $20.98 | 2020 | |
| Elekta, INC. | $16.71 | 2025 | Flexitron Hdr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Garman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.